Intestinal fate of 5-aminosalicylic acid: Regional and systemic kinetic studies in relation to inflammatory bowel disease

Pharmacology and Toxicology

Volumn 81, Issue SUPPL. 2, 1997, Pages 1-30

  Bondesen, Stig ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

DELAYED RELEASE FORMULATION; ENTERITIS; HUMAN; INTESTINE; METABOLISM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELAYED-ACTION PREPARATIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MESALAMINE; SULFASALAZINE;

EID: 28244486799     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb01944.x     Document Type: Article

References (134)

1. Ahnfelt-Rønne, I., O. H. Nielsen, A. Christensen, E. Langholz, V. Binder & P. Riis: Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990, 98, 1162-1169.
2. Allgayer, H., N. O. Ahnfelt, W. Kruis, U. Klotz, K. Frank-Holmberg, H. N. Soderberg & G. Paumgartner: Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterohgy 1989, 97, 38-41.
3. Allgayer, H., W. Kruis, J. Eisenburg & G. Paumgartner: Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 1984, 26, 275-277.
4. Allgayer, H., J. Sonnenbichler, W. Kruis & G. Paumgartner: Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites. Arzneimittelforschung 1985, 35, 1457-1459.
5. Almer, S., B. Norlander, M. Strom & H. Osterwald: Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. Scand. J. Gastroenterology 1991, 26(3), 327-335.
6. Astbury, C., A. J. Taggart, L. Juby, L. Zebouni & H. A. Bird: Comparison of the single-dose pharmacokinetics of sulphasalazine in theumatoid arthritis and inflammatory bowel disease. Ann. Rheum. Dis. 1990, 49, 587-590.
7. Anthonisen, P., F. Barany, O. Folkenborg, et al.: The clinical effect of salazosulphapyridine in Crohn's disease. A controlled double-blind study. Scand. J. Gastroenterol. 1974, 9, 549-554.
8. Azad Khan, A. K., J. Piris & S. C. Truelove: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977, 29(2), 892-895.
9. Azad Khan, A. K., G. Guthrie, J. H. Johnston, S. C. Truelove & D. H. Williamson: Tissue and bacterial splitting of sulphasalazine. Clin. Science 1983, 64, 349-354.
10. Azad Khan, A. K. & D. T. Howes, J. Piris & S. C. Truelove: Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980, 21, 232-240.
11. Azad Khan, A. K. & S. C. Truelove & J. K. Aronson: The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br. J. Clin. Pharmacol. 1982, 13, 523-528.
12. Azad Khan, A. K. & S. C. Truelove: Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis. Gut 1980, 21, 706-710.
13. Back, D. J. & S. M. Rogers: Review: first pass metabolism by the gastrointestinal metabolism. Aliment Pharmacol. Therap. 1987, 1, 339-357.
14. Baron, J. H., A. M. Connell, J. E. Lennard-Jones & F. Avery Jones: Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962, ii, 1094-1096.
15. Binder, V. S. Halskov, E. Hvidberg, E. Kristensen, P. Riis, L. Tougaard, et al.: A controlled study of 5-acetaminosalicylic acid as enema in ulcerative colitis. Scand. J. Gastroenterol. 1981, 16, 1122.
16. Bondesen, S., S. N. Rasmussen, J. Rask-Madsen, O. H. Nielsen, K. Lauritsen, V. Binder, S. H. Hansen & E. F. Hvidberg: 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med. Scand. 1987, 221, 227-242.
17. Calder, I. C., C. C. Funder, C. R. Green, K. N. Ham & J. D. Tange: Nephrotoxic lesions from 5-amino-salicylic acid. BMJ 1972, 1, 152-154.
18. Campieri, M., G. A. Lanfranchi, G. Bazzocchi, C. Brignola, F. Sarti, G. Franzin, A. Battocchia, G. Labo & P. R. Dal-Monte: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981, 2, 270-271.
19. Campieri, M., G. A. Lanfranchi, S. Boschi, et al.: Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985, 26, 400-405.
20. Campieri, M., G. A. Lanfranchi, C. Brignola, et al.: Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis. Colon Rectum 1986, 29, 108-110.
21. Christensen, L. A., J. Fallingborg, K. Abildgaard, B. A. Jacobsen, G. Sanchez, S. H. Hansen, S. Bondesen, E. F. Hvidberg & S. N. Rasmussen: Topical and systemic availability of 5-aminosalicylate: Comparisons of three controlled release preparations in man. Aliment Pharmacol. Ther. 1990, 4, 523-533.
22. Christensen, L. A., O. Slot, G. Sanchez, J. Boserup, S. N. Rasmussen, S. Bondesen, S. H. Hansen & E. F. Hvidberg: Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 1987, 23, 1062-1070.
23. Corey, A. E., G. M. Rose & J. D. Conklin: Bioavailability of single and multiple doses of enteric coated mesalamine and sulphasalazine. J. Internat. Med. Res. 1990, 6, 441-453.
24. Dale, K. Y., A. T. Elvin, B. Morrill, L. S. Eichmeier, R. C. Lanman, M. B. Lanman & D. H. Giesing: Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin. Pharmacol. Ther. 1990, 48, 26-33.
25. Danish 5-ASA group: Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig. Dis. Sci. 1987, 32, 598-602.
26. Das, K. M.: Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. Postgrad. Med. 1983, 74(6), 141-148, 150-151.
27. Das, K. M., M. A. Eastwood, J. P. A. McManus & W. Sircus: The metabolism of salicylsazosulpha-pyridine in ulcerative colitis. Gut 1973, 14, 631-5641.
28. Davis, S. S., J. G. Hardy & J. W. Fara: Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27, 886-892.
29. Day, J. M. & J. B. Houston: Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease. Br. J. Clin. Pharmacol. 1980, 9, 91-94.
30. de Franchis, R., M. Vecchi, L. Carpinelli, G. Meucci & Torgano: Comparison of efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis: a metaanalysis. Eur. J. Gastroenterol. Hepatol. 1993, 5, 505-510.
31. De Mey, C. & I. Meineke: Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). Br. J. Clin. Pharmacol. 1992, 33(2): 179-182.
32. De Vos, M., H. Verdievel, R. Schoonjans, M. Praet, M. Bogaert & F. Barbier: Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992, 33, 1338-1342.
33. Dew, M. J., P. Ebden, N. S. Kidwai, G. Lee, B. K. Evans & J. Rhodes: Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. Br. J. Clin. Pharmacol. 1984, 17, 474-476.
34. Dick, A. P., M. J. Grayson, R. G. Carpenter & A. Petrie: Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964, i: 437-442.
35. Dissanayake, A. S. & S. C. Truelove: A controlled long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 1973, 14, 923-926.
36. Dull, B. J., K. Salata, A. van Langenhove & ÅP. Goldman:5-aminosalicylate: Oxidation by activated leukocytes and protection of cultured cells from oxidative damage. Biochem. Pharmacol. 1987, 36, 2467-2472.
37. Ewe, K. Herfarth, Malchow & H. J. Jesdinsky: Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989, 42, 224-232.
38. Fischer, C., K. Maier, E. Stumpf, U. von-Gaisberg & U. Klotz: Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur. J. Clin. Pharmacol. 1983, 25, 511-515.
39. Friedman, L. S., J. M. Richter, S. E. Kirkham, H. J. De-Monaco & R. J. May: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am. J. Gastroenterol. 1986, 81, 412-418.
40. Giaffer, M. H., C. J. O'Brien & C. D. Holdsworth: Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol. Ther. 1992, 6(1), 51-59.
41. Goebell, H., U. Klotz, B. Nehlsen & P. Layer: Oroileal transit of slow release 5-aminosalicylic acid. Gut 1993, 34, 669-675.
42. Goldman, P.: Will there be a next generation of sulfasalazine? Gastroenterology 1982, 83, 1138-1141.
43. Greenfield, S. M., N. A. Punchard, J. P. Teare & R. P. Thompson: Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol. Ther. 1993, 7(4), 369-383.
44. Grisham, M. B. & D. N. Granger: 5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. Dig. Dis. Sci. 1989, 34, 573-578.
45. Grisham, M. B., K. Ware, S. Marshall, T. Yamada & I. S. Sandhu: Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects. Dig. Dis. Sci. 1992, 37, 1383-1389.
46. Hanauer, S., J. Schwartz, M. Robinson, W. Roufail, S. Arora, J. Cello & M. Safdi: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol, 1993, 88(8), 1188-1197.
47. Hanauer, S. B. & G. Stathopoulos: Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety 1991, 6(3), 192-219.
48. Hansen, S. H.: Assay of 5-aminosalicylic and its acetylated metabolite in biological fluids by hiigh-performance liquid chromatography on dynamically modified silica. J. Chromatogr. 1981, 162, 237-243.
49. Hansson, K. A.: Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine. Acta Pharm. Suec. 1973, 10, 153-155.
50. Hardy, J. D., J. N. C. Healey, S. W. Lee & J. R. Reynolds: Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Aliment Pharmacol. Therap. 1987, 1, 209-217.
51. Hardy, J. G., W. J. Harvey, R. A. Sparrow, G. B. Marshall, K. P. Steed, M. Macarios & I. R. Wilding: Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. J. Clin. Pharmacol. 1993, 33(8), 712-718.
52. Houston, J. B., J. Day & J. Walker: Azo reduction of sulphasalazine in healthy volunteers. Br. J. Clin. Pharmacol. 1982, 14, 395-398.
53. Houston J. B. & M. K. Cassidy: Rate-limiting steps in metabolite kinetics: formation of 5-acetyl-aminosalicylate after administration of 5-aminosalicylate. J. Pharm. Pharmacol. 1982, 34, 536-538.
54. Ireland, A., J. D. Priddle & D. P. Jewell: Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin. Sci. 1990, 78, 105-111.
55. Ireland, A., J. D. Priddle & D. P. Jewell: Comparison of 5-aminosalicylic acid and N-acetylaminosalicylic acid uptake by the isolated human colonic epithelial cell. Gut 1992, 33(10), 1343-1347.
56. Jacobsen, B. A., K. Abildgaard, H. H. Rasmussen, L. A. Christensen, J. Fallingborg, S. H. Hansen & S. N. Rasmussen: Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand. J. Gastroenterology 1991, 26(4), 374-378.
57. Jarnerot, G.: Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989, 37, 73-86.
58. Jensen, J., C. Cornell, C. E. Olsen, S. Bondesen, J. Chrislensen, L. A. Christensen, J. Tjornelund & S. H. Hansen: Identification of oxidation products of 5-aminosalicylic acid in faeces and the study of their formation in vitro. Biochem. Pharmacol. 1993, 45(6), 1201-1209.
59. Kellow, J. E., T. J. Borody, S. F. Phillips, A. C. Haddad & M. L. Brown: Sulfapyridine appearance in plasma after salicylazosulfapyridine. Gastroenterology 1989, 91, 396-400.
60. Kiilerich, S., K. Ladefoged, T. Rannem, P. J. Ranløv and the Danish Olsalazine study group: Prophylactic effects of sulfasalazine during 12 months naintenance treatment of ulcerative colitis. Gut 1992, 33, 252-255.
61. Kirsner, J. B.: Inflammatory bowel disease. Part I: Nature and pathogenesis. Dis. Mon. 1991, 37, 605-666.
62. Kirsner, J. B.: Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. Dis. Mon. 1991, 37, 669-746.
63. Kjeldsen, J. & O. B. Schaffalitzky de Muckadell: Assessment of disease Severity and activity in inflammatory bowel disease. Review. Scand. J. Gastroenterol. 1993, 28, 1-9.
64. Klotz, U.: Clinical pharmacokinetics of sulphasalazine, its metabolites, and other producls of 5-aminosalicylic acid. Clin. Pharmacokinet. 1985, 10, 285-302.
65. Larouche, J., J. Morais, M. Picard, C. Lambert, J. Spenard, H. Landriault, G. Kennedy & P. Poitras: Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol. Ther. 1995, 9(3), 315-320.
66. Lauritsen, K., J. Hansen, M. Ryde & J. Rask-Madsen: CoIonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984, 86, 1496-1500.
67. Lauritsen, K., L. S. Laursen, K. Bukhave & J., Rask-Madsen: Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986, 91, 837-844.
68. Laursen, L. S., K. Stokholm, K. Bukhave, J. Rask-Madsen & K. Lauritsen: Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparisons of intraluminal colonic concentrations, serum values and urinary excretions. Gut 1990, 31, 1271-1276.
69. Layer, P. H., H. Goebell, J. Keller, A. Dignass & U. Klotz: Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995, 108(5), 1427-1433.
70. Malchow, H., K. Ewe, J. W. Brandes, H. Goebell, H. Ehms, H. Sommer & H. Jesdinsky: European cooperative Crohn's disease study (ECCDS): Results of drug treatment Gastroenterology 1984, 86, 249-266.
71. Mardini, H. Al, D. C. Lindsay, C. M. Deighton & C. O. Record: Effect of polymer coating on faecal recovery of ingested. 5-aminosalicylic acid in patients with ulcerative colitis. Gut 1987, 28, 1084-1089.
72. Marshall J. K. & E. J. Irvine: Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol. Ther. 1995, 9(3), 293-300.
73. McLeod, R. S., Z. Coehn, B. J. Vari, J. E. Blair & G. R. Greenberg: The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa) in humans. Dis. Col. Rect. 1990, 33, 21-25.
74. Meese, C. O. C. Fischer & U. Klotz: Is N-acetylation of 5-aminosalicylic acid reversible in man? Br. J. Clin. Pharmacol. 1984, 18, 612-615.
75. Messori, A., C. Brignola, G. Trallori, R. Rampazzo, G. Bardazzi, C. Belloli, G. d'Albasio, G. De Simone & N. Martini: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 1994, 89(5), 692-698.
76. Meyers, S. & H. D. Janowitz: Natural history of Crohn's disease: An analytical review of the placebo lesson. Gastroenterology 1984, 87, 1189-1192.
77. Misiewicz, J. J., J. E. Lennard-Jones, A. M. Connell, J. H. Baron & F. Avery Jones: Controlled trial of sulphaslazine in maintenance therapy for ulcerative colitis. Lancet 1965, i, 185-188.
78. Mulder, C. J., G. N. Tytgat, I. T. Weterman, W. Dekker, P. Blok, M. Schrijver & H. van der Heide: Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988, 95, 1449-1453.
79. Myers, B., D. N. W. Evans, J. Rhodes, B. R. Hughes, M. G. Lee, A. Richens & D. Richards: Metabolism and urinary excretion of 5-amino-salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987, 28, 196-200.
80. Norlander, B., R. Gotthard & M. Strom: Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's diasese or ulcerative colitis. Alimentary Pharmacology & Therapeutics 1991, 5(3), 291-300.
81. Orholm, M., L. Iselius, A. Sorensen, P. Munkholm, E. Langholz & V. Binder: Investigation of chronic inflammatory bowel diseases bycomplex segregational analysis. BMJ 1993, 306, 20-24.
82. Peppercorn, M. A. & P. Goldman: Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973, 64, 240-245.
83. Peppercorn, M. A. & P. Goldman: The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. .J Pharmacol. Exp. Therap. 1972, 181, 555-562.
84. Pieniaszek, H. J. Jr. & T. R. Bates: Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. Res. Commun. Chem. Pathol. Pharmacol. 1975, 12, 571-581.
85. Pieniaszek, H. J. Jr. & T. R. Bates: Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J. Pharm. Sci. 1979, 68, 1323-1325.
86. Pieniaszek, H. J., D. E. Resetarits, W. W. Wilferth, D. E. Blumenthal & T. E. Bates: Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. J. Clin. Pharmacol. 1979, 1, 39-45.
87. Prantera, C., F. Pallone, G. Brunetti, M. Cottone & M. Miglioli: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group Gastroenterology 1992, 103, 363-368.
88. Rachmilewitz, D.: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of actived ulcerative colitis: a randomized trial. BMJ 1989, 298, 82-86.
89. Rasmussen, S. N., V. Binder, K. Maier, S. Bondesen, C. Fischer, U. Klotz, S. H. Hansen & E. F. Hvidberg: Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983, 85, 1350-1353.
90. Rasmussen, S. N., S. Bondesen & E. F. Hvidberg: 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982, 83, 1062-1070.
91. Rasmussen, S. N., K. Lauritsen, U. Tage-Jensen, et al.: 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand. J. Gastroenterol. 1987, 22, 877-883.
92. Rijk, M. C., R. A. van Hogezand, H. J. J. van Lier & J. H. M. van Tongeren: Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. Ann. Int. Med. 1991, 114, 445-450.
93. Rijk, M. C., R. A. van Hogezand, A. van Schaik & J. H. van Tongeren: Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand. J. Gastroenterol. 1989, 24, 1179-1185.
94. Rijk, M. C., A. van Schaik & J. H. van Tongeren: Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand. J. Gastroenterol. 1988, 23, 107-112.
95. Rijk, M. C., A. van Schaik & J. H. D. van Tongeren: Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand. J. Gastroenterol. 1992, 27(10), 863-868.
96. Riley, S. A., V. Mani, M. J. Goodman, M. E. Herd, S. Dutt & L. A. Turnberg: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988, 29, 669-674.
97. Riley, S. A., I. A. Tavares, A. Bennett & V. Mani: Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br. J. Clin. Pharmacol. 1988, 26, 173-177.
98. Roediger, W., G. Schapel, M. Lawson, B. Radcliffe & S. Nance: Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis. Biochem. Pharmacol. 1986, 35, 221-225.
99. Salomon, P., A. Kornbluth, J. Aisenberg & H. D. Janowitz: How effective are current drugs for Crohn's disease. A meta-analysis. J. Clin. Gastroenterol. 1992, 14, 211-215.
100. Sandberg-Gertzén, H., M. Ryde & G. Järnerot: Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand. J. Gastroenterol. 1983, 18, 107-111.
101. Schninsky, C. A., D. H. Cort, F. Shanahan, B. J. Powers, J. T. Sessions, R. E. Pruit, et al.: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. Ann. Int. Med. 1991, 115, 350-355.
102. Schröder, H. & D. E. S. Campbell: Absorption,metabolism and excretion of salicylazosulfapyridine in man. Clin. Pharmacol. Ther. 1972, 13, 539-551.
103. Schöder, H. & B. E. Gustafsson: Azo reduction of salicyl-azosulphapyridine in germ free and concentional rats. Xenobiotica 1973, 4, 225-231.
104. Schröder, H. & A. K. Johansson: Redox potential in caecal contents of the rat and azo reduction of salicyl-azo-sulphapyridine. Xenobiotica 1973, 3, 233-246.
105. Schroeder, K. W., W. J. Tremaine & D. M. Ilstrup: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987, 317, 1625-1629.
106. Shafii, A., J. R. Chowdhury & K. M. Das: Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. Am. J. Gastroenterol. 1982, 77, 297-299.
107. Shah, S. A. & M. A. Peppercorn: Inflammatory bowel disease therapy: an update. Compr-Ther. 1995, 21, 296-302.
108. Shanahan, F. & S. Targan: Medical treatment of inflammatory bowel disease. Annu. Rev. Med. 1992, 43, 125-133.
109. Singleton, J. W., S. B. Hanauer, G. L. Gitnick, M. A. Peppercorn, M. G. Robinson, L. D. Wruble & E. L. Krawitt: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterohgy 1993, 104(5), 1293-1301.
110. Spiller, R. C.: Where do all the tablets go? Gut 1986, 27, 879-885.
111. Steinhart, A. H., D. Hemphill & G. R. Greenberg: Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am. J. Gastroenterol. 1994, 89, 2116-2124.
112. Stolz, A., Nörtemann & H.-J. Knackmuss: Bacterial metabolism of 5-aminosalicylic acid. Biochem. J. 1992, 282, 675-680.
113. Summers, R. W., D. M. Switz, J. T. Sessions, J. M. Bectel, W. R. Best, F. Kern & J. W. Singleton: National cooperative Crohn's disease study: result of drug treatment. Gastroenterology 1979, 77, 847-869.
114. Sutherland, L. R., F. Martin, S. Greer, M. Robinson, N. Greenberger, F. Saibil, T. Martin, J. Sparr, Prokipchuk & L. Boregn: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92, 1894-1898.
115. Sutherland, L. R., G. R. May & E. A. Shaffer: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Intern. Med. 1993, 118, 540-549.
116. Svartz, N.: Salazopyrin, a new sulfanilamide preparation. Acta Med. Scand. 1942, 110, 577-598.
117. Swift, G. L., C. M. Mills, J. Rhodes, B. K. Evans, A. Bennett & I. A. Tavares: A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine. Aliment Pharmacol. Ther. 1992, 6, 259-266.
118. Tiel van Buul, M. M., C. J. Mulder, E. A. van Royen, E. H. Wiltink & G. N. Tytgat: Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis. Clinical Pharmacokinetics 1991, 20(3), 247-251.
119. Tjornelund, J., S. H. Hansen & C. Cornell: New metabolites of the drug 5-aminosalicylic acid. I. N-β-D-glucopyranosyl-5-aminosalicylic acid. Xenobiotica 1989, 19, 891-899.
120. Tjornelund, J., S. H. Hansen & C. Cornell: New metabolites of the drug 5-aminosalicylic acid. II. N-formyl-5-aminosalicylic acid. Xenobiotica 1991, 21, 605-612.
121. Travis, S. P. L. & D. P. Jewell: Salicylates for ulcerative colitis - their mode of action. Pharmacol. Ther. 1994, 63, 135-161.
122. Travis, S. P. L., C. Tysk, H. J. de Silva, H. Sandberg-Gertzén, D. P. Jewell & C. Järnerot: Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994, 35, 1282-1286.
123. Ursing, B., T. Alm, F. Barany, Bergelin, K. G. Norlin, J. Hoevels, B. Huitfeldt, G. Järnerot, U. Krause, A. Krook, N. Lindström, Ö. Nordle & A. Rosen: Metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. Gastroenterology 1982, 83, 550-562.
124. van Hees, P. A. M., J. H. Bakker & J. H. van-Tongeren: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980, 21, 632-635.
125. van Hees, P. A. M., J. H. Tuinte, J. M. van-Rossum & J. H. van-Tongeren: Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 1979, 20, 300-304.
126. van Hees, P. A. M. & H. J. J. van Lier, P. H. van Elteren, W. M. M. Driessen, R. A. van Hogezand, G. P. M. Ten Velde, J. H. Bakker & J. H. M. van Tongeren: Effect of sulphasalazine in patients with active Crohn's disease: controlled double-blind study. Gut 1981, 22, 404-409.
127. van Hees, P. A. M. & J. H. M. van Tongeren: Compliance to therapy in patients on a maintenance dose of sulfasalazine. J. Clin. Gastroenterol. 1982, 4, 333-336.
128. van Hogezand, R. A., H. M. Kennis, A. van Schaik, J. P. Koopman & P. A. M. van Hees: Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions under aerobic and anaerobic conditions. Eur. J. Clin. Pharmacol. 1992, 43, 189-192.
129. van Hogezand, R. A., P. A. M. van Hees, J. P. W. M. van Gorp, H. J. J. van Lier, P. Wesseling, et al.: Double blind comparison of 5-aminosalicylic acid and acetyl 5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol. Therap. 1988, 2, 33-40.
130. Vitti, R. A., F. Meyers, L. C. Knight, J. A. Siegel, L. S. Malmud & R. S. Fisher: Quantitative distribution of radiolabelled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig. Dis. Sci. 1989, 34, 1792-1797.
131. Wenckert, A., M. Kristensen, A. E. Eklund, et al.: The long-term prophylactic effect of salazosulphapyridine in primarily resected patients with Crohn's disease. A double-blind trial. Scand. J. Gastroenterol. 1978, 13, 161-167.
132. Willoughby, C. P., J. Piris & S. C. Truelove: The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand. J. Gastroenterol. 1980, 15, 715-719.
133. Wright, J. P., E. A. O'Keefe, L. Cuming & K. Jaskiewicz: Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig. Dis. Sci. 1993, 38(10), 1837-1842.
134. Yashuara, M., Y. Kurosaki, T. Kimura & H. Sezaki: Drug elimination function of rat small intestine: metabolism and intraluminal excretion. Biochemical Pharmacology 1984, 33, 3131-3136.